“…Changes in CBF ( n = 7–8 mic in each group) were assessed in three trials (5‐ to 10‐min intervals). CBF responses to whisker stimulation were repeated in the presence of the following inhibitors administered topically onto the brain surface of separate groups of animals: HET0016 (inhibitor of 20‐hydroxyeicosatrienoic acid (20‐HETE) production, 10 −6 mol L −1 for 30 min; Cayman Chemicals, Ann Arbor, MI, USA) (Liu et al ., 2008), MS‐PPOH (inhibitor of EET production, 20 × 10 −6 mol L −1 for 30 min; Cayman Chemicals) (Shi et al ., 2008), L‐NAME (N ω ‐Nitro‐L‐arginine methyl ester, inhibitor of nitric oxide synthase, 10 −4 mol L −1 for 20 min; Sigma‐Aldrich, St. Louis, MO, U.S.A.), apocynin (inhibitor of NADPH oxidases, 3 × 10 −4 mol L −1 for 30 min; Cayman Chemicals), fluoroacetate sodium (inhibitor of the tricarboxylic acid cycle predominantly in glial cells, 10 −4 mol L −1 min; Sigma‐Aldrich, St. Louis, MO, U.S.A.) (Fonnum et al ., 1997; Lecrux et al ., 2012), indomethacin (cyclooxygenase inhibitor, 5 × 10 −4 mol L −1 ; Sigma‐Aldrich, St. Louis, MO, U.S.A.) (Kitaura et al ., 2007), MPEP (6‐Methyl‐2‐(phenylethynyl)pyridine hydrochloride, group I metabotropic glutamate receptors (mGluR) subtype 5 antagonist, 5 × 10 −5 mol L −1 ) (Zonta et al ., 2003), and the NMDA (N‐methyl‐D‐aspartate) receptor antagonist D‐APV (D‐2‐Amino‐5‐Phosphonovaleric acid, 5 × 10 −5 mol L −1 ; Cayman Chemicals) (Stobart et al ., 2013). In a separate series of experiments ( n = 8 in each group), CBF responses to topical administration of L‐glutamate (500 μmol L −1 ) (Hall et al ., 2014) were determined in the absence and presence of MPEP (5 × 10 −5 mol L −1 ) and D‐APV (5 × 10 −5 mol L −1 ) (Stobart et al ., 2013).…”